Mississippi House Bill HB393

Mississippi 2023 Regular Session

• Introduced: 1/10/23
• Refer: 1/10/23
• Engrossed: 1/19/23
• Refer: 2/15/23
• Failed: 2/28/23

Caption

Pseudoephedrine and ephedrine; extend repealer on authority to sell and purchase without a prescription certain products containing.

Impact

The implications of HB393 on state law are significant as it continues to authorize the over-the-counter sale of certain quantities of pseudoephedrine and ephedrine. This legislative measure is crucial in managing regulations concerning the sale of these substances, which are often used as precursors in illicit drug manufacturing. By doing so, the bill aims to balance consumer accessibility with public health and safety concerns, while specifying the necessity of electronic tracking and record-keeping to support lawful sales.

Summary

House Bill 393 aims to amend Section 73-21-124 of the Mississippi Code of 1972, which governs the sale and purchase of products containing pseudoephedrine and ephedrine in registered pharmacies. The bill extends the previously established repeal date of this statute, allowing individuals to continue purchasing these products without a prescription, under certain conditions. Specifically, the bill maintains that a person may acquire up to 3.6 grams daily and 7.2 grams every thirty days, while placing strong emphasis on restrictions and logging of transactions to combat misuse.

Sentiment

The sentiment surrounding HB393 appears generally supportive within the legislature, as evidenced by its unanimous passage in the House with a vote of 117-0. Representatives likely understand the public necessity for these medications, particularly in treating conditions like allergies or sinus issues. However, there may be underlying concerns about the potential for substance misuse, prompting rigorous tracking measures to be included in the provisions of the bill.

Contention

While no overt major points of contention are identified in the discussions around HB393, the ongoing battle between accessibility of necessary drugs and the prevention of their misuse looms large. Stakeholders in the pharmaceutical industry may support the bill for its potential to preserve business operations, while public health advocates might push for stronger restrictions to deter misuse. Nonetheless, the bill maintains a legislative pathway for controlled access, demonstrating a compromise between facilitating legitimate use and curbing illegal activities.